Annovis Bio, Inc. Operating Cash Flow
Annovis Bio, Inc. (ANVS) reported Operating Cash Flow of -$30.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- Annovis Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$21.91M.
- Annovis Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$9.01M.
- Annovis Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$8.93M.
- Annovis Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$3.49M.
- Annovis Bio, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$25.62M.
- Annovis Bio, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$21.89M.
- Annovis Bio, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$39.97M.
- Annovis Bio, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$17.31M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$21.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$30.93M 10-Q · filed 2026-08-14 | -$39.85M derived: sum of 3 quarters · filed 2026-08-14 | -$43.34M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$9.01M 10-Q · filed 2026-05-15 | -$17.94M derived: sum of 2 quarters · filed 2026-05-15 | -$21.43M derived: sum of 3 quarters · filed 2026-05-15 | -$26.53M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$8.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$12.41M derived: sum of 2 quarters · filed 2026-03-13 | -$17.52M derived: sum of 3 quarters · filed 2026-08-14 | -$25.62M 10-K · filed 2026-03-13 |
| 2025-09-30 | -$3.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$8.59M derived: sum of 2 quarters · filed 2026-08-14 | -$16.69M 10-Q · filed 2025-11-12 | -$24.98M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$5.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$13.21M 10-Q · filed 2026-08-14 | -$21.49M derived: sum of 3 quarters · filed 2026-08-14 | -$24.69M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$8.10M 10-Q · filed 2026-05-15 | -$16.38M derived: sum of 2 quarters · filed 2026-05-15 | -$19.59M derived: sum of 3 quarters · filed 2026-05-15 | -$22.96M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$8.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$11.49M derived: sum of 2 quarters · filed 2026-03-13 | -$14.86M derived: sum of 3 quarters · filed 2026-03-13 | -$21.89M 10-K · filed 2026-03-13 |
| 2024-09-30 | -$3.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$6.58M derived: sum of 2 quarters · filed 2025-11-12 | -$13.61M 10-Q · filed 2025-11-12 | -$22.97M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$3.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$10.41M 10-Q · filed 2025-08-12 | -$19.77M derived: sum of 3 quarters · filed 2025-08-12 | -$29.14M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$7.03M 10-Q · filed 2025-05-13 | -$16.40M derived: sum of 2 quarters · filed 2025-05-13 | -$25.77M derived: sum of 3 quarters · filed 2025-05-13 | -$35.37M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$9.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | -$18.73M derived: sum of 2 quarters · filed 2025-03-21 | -$28.34M derived: sum of 3 quarters · filed 2025-03-21 | -$39.97M 10-K · filed 2025-03-21 |
| 2023-09-30 | -$9.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$18.98M derived: sum of 2 quarters · filed 2024-11-08 | -$30.60M 10-Q · filed 2024-11-08 | -$34.21M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | -$9.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$21.23M 10-Q · filed 2024-08-14 | -$24.84M derived: sum of 3 quarters · filed 2024-08-14 | -$28.83M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$11.63M 10-Q · filed 2024-05-10 | -$15.24M derived: sum of 2 quarters · filed 2024-05-10 | -$19.22M derived: sum of 3 quarters · filed 2024-05-10 | -$25.92M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$3.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$7.60M derived: sum of 2 quarters · filed 2024-03-29 | -$14.29M derived: sum of 3 quarters · filed 2024-03-29 | -$17.31M 10-K · filed 2024-03-29 |
| 2022-09-30 | -$3.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$10.68M derived: sum of 2 quarters · filed 2023-11-08 | -$13.70M 10-Q · filed 2023-11-08 | -$15.47M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$6.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$9.72M 10-Q · filed 2023-08-14 | -$11.49M derived: sum of 3 quarters · filed 2023-08-14 | -$13.23M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$3.02M 10-Q · filed 2023-05-10 | -$4.79M derived: sum of 2 quarters · filed 2023-05-10 | -$6.53M derived: sum of 3 quarters · filed 2023-05-10 | -$9.68M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$3.51M derived: sum of 2 quarters · filed 2023-03-31 | -$6.66M derived: sum of 3 quarters · filed 2023-03-31 | -$9.13M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$4.89M derived: sum of 2 quarters · filed 2022-11-08 | -$7.36M 10-Q · filed 2022-11-08 | -$8.13M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$3.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$5.62M 10-Q · filed 2022-08-08 | -$6.39M derived: sum of 3 quarters · filed 2022-08-08 | -$7.31M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$2.47M 10-Q · filed 2022-05-04 | -$3.24M derived: sum of 2 quarters · filed 2022-05-04 | -$4.16M derived: sum of 3 quarters · filed 2022-05-04 | -$5.48M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | -$765.95K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | -$1.69M derived: sum of 2 quarters · filed 2022-03-02 | -$3.00M derived: sum of 3 quarters · filed 2022-03-02 | -$3.97M 10-K · filed 2022-03-02 |
| 2020-09-30 | -$922.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$2.23M derived: sum of 2 quarters · filed 2021-11-03 | -$3.20M 10-Q · filed 2021-11-03 | -$3.26M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | -$1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | -$2.28M 10-Q · filed 2021-07-28 | -$2.33M derived: sum of 3 quarters · filed 2021-07-28 | -$2.38M derived: sum of 4 quarters · filed 2021-07-28 |
| 2020-03-31 | -$970.40K 10-Q · filed 2021-05-06 | -$1.02M derived: sum of 2 quarters · filed 2021-05-06 | -$1.07M derived: sum of 3 quarters · filed 2021-05-06 | -$1.22M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | -$52.53K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | -$97.21K derived: sum of 2 quarters · filed 2021-03-03 | -$247.80K derived: sum of 3 quarters · filed 2021-03-03 | -$476.54K 10-K · filed 2021-03-03 |
| 2019-09-30 | -$44.68K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$195.28K derived: sum of 2 quarters · filed 2020-11-04 | -$424.01K 10-Q · filed 2020-11-04 | |
| 2019-06-30 | -$150.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | -$379.33K 10-Q · filed 2020-07-29 | ||
| 2019-03-31 | -$228.74K 10-Q · filed 2020-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |